GlycoMimetics to Present at 18th Annual BIO CEO & Investor Conference
To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.
About
GlycoMimetics's wholly-owned drug candidate (GMI-1271) for AML and other
blood disorders is also in clinical trials.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160201006091/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media